Originally published as JCO Early Release 10.1200/JCO.2005.01.8234 on October 3 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hainsworth, J. D. Articles by Greco, A. Search for Related Content PubMed PubMed Citation Articles by Hainsworth, J. D. Articles by Greco, A. Social Bookmarking                            What's this?

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

From the Sarah Cannon Research Institute; and Vanderbilt-Ingram Cancer Center, Nashville, TN

Address reprint requests to John D. Hainsworth, MD, Sarah Cannon Research Institute, 250 25th Ave N, Suite 110, Nashville, TN 37203; e-mail: jhainsworth{at}tnonc.com

PURPOSE: To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma.

PATIENTS AND METHODS: Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally daily. Patients were reevaluated after 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progression.

RESULTS: Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective responses to treatment, and an additional 36 patients (61%) had stable disease after 8 weeks of treatment. Only eight patients' (14%) disease had progressed at this time point. The median and 1-year progression-free survivals were 11 months and 43%, respectively. After a median follow-up of 15 months, median survival has not been reached; survival at 18 months was 60%. Treatment was generally well tolerated; only two patients discontinued treatment because of toxicity (skin rash). Grade 1/2 skin rash and diarrhea were the most frequent treatment-related toxicities.

CONCLUSION: The combination of bevacizumab and erlotinib is an effective and well-tolerated treatment for patients with advanced renal cell carcinoma. The efficacy of these two drugs in combination suggests that targeting of separate pathways critical to tumor growth and dissemination may achieve results superior to either drug as a single agent. Additional development of this and other combinations of targeted agents is warranted.

Supported by grants from Genentech, Inc, and the Minnie Pearl Cancer Foundation.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Tsavachidou-Fenner, N. Tannir, P. Tamboli, W. Liu, D. Petillo, B. Teh, G. B. Mills, and E. Jonasch Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma Ann. Onc., August 1, 2010; 21(8): 1599 - 1606. [Abstract] [Full Text] [PDF]

				B. Escudier How to Interpret Phase II Data for Everolimus Plus Bevacizumab in Renal Cell Carcinoma J. Clin. Oncol., May 1, 2010; 28(13): 2125 - 2126. [Full Text] [PDF]

				M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann. Onc., February 11, 2010; (2010) mdq020v1. [Abstract] [Full Text] [PDF]

				C. Vaklavas, D. Lenihan, R. Kurzrock, and A. M. Tsimberidou Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target? Oncologist, February 1, 2010; 15(2): 130 - 141. [Abstract] [Full Text] [PDF]

				A. K. Agarwala and N. H. Hanna Review: Advanced non-small cell lung cancer: the role of maintenance therapy Therapeutic Advances in Medical Oncology, January 1, 2010; 2(1): 17 - 23. [Abstract] [PDF]

				M. S. Gordon, M. Hussey, R. B. Nagle, P. N. Lara Jr, P. C. Mack, J. Dutcher, W. Samlowski, J. I. Clark, D. I. Quinn, C.-X. Pan, et al. Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317 J. Clin. Oncol., December 1, 2009; 27(34): 5788 - 5793. [Abstract] [Full Text] [PDF]

				N. Starling, D. Watkins, D. Cunningham, J. Thomas, J. Webb, G. Brown, K. Thomas, J. Oates, and I. Chau Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5499 - 5505. [Abstract] [Full Text] [PDF]

				R. J. Cersosimo Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2 Am. J. Health Syst. Pharm., September 15, 2009; 66(18): 1625 - 1633. [Abstract] [Full Text] [PDF]

				J. M.G. Larkin, E. L.S. Kipps, C. J. Powell, and C. Swanton Review: Systemic therapy for advanced renal cell carcinoma Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 15 - 27. [Abstract] [PDF]

				N. Schicher, V. Paulitschke, A. Swoboda, R. Kunstfeld, R. Loewe, P. Pilarski, H. Pehamberger, and C. Hoeller Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma Clin. Cancer Res., May 15, 2009; 15(10): 3495 - 3502. [Abstract] [Full Text] [PDF]

				M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, et al. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL J. Clin. Oncol., March 10, 2009; 27(8): 1227 - 1234. [Abstract] [Full Text] [PDF]

				M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7878 - 7883. [Abstract] [Full Text] [PDF]

				R. L. Nachman and S. Rafii Platelets, Petechiae, and Preservation of the Vascular Wall N. Engl. J. Med., September 18, 2008; 359(12): 1261 - 1270. [Full Text] [PDF]

				N. S. Azad, E. M. Posadas, V. E. Kwitkowski, S. M. Steinberg, L. Jain, C. M. Annunziata, L. Minasian, G. Sarosy, H. L. Kotz, A. Premkumar, et al. Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity J. Clin. Oncol., August 1, 2008; 26(22): 3709 - 3714. [Abstract] [Full Text] [PDF]

				C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncology, August 1, 2008; 10(4): 624 - 630. [Abstract] [Full Text] [PDF]

				A. Ravaud, R. Hawkins, J. P. Gardner, H. von der Maase, N. Zantl, P. Harper, F. Rolland, B. Audhuy, J.-P. Machiels, F. Petavy, et al. Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial J. Clin. Oncol., May 10, 2008; 26(14): 2285 - 2291. [Abstract] [Full Text] [PDF]

				J. Waxman, L. Kenny, and S. Ngan New treatments for kidney cancer BMJ, March 29, 2008; 336(7646): 681 - 682. [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]

				S. Ebbinghaus, M. Hussain, N. Tannir, M. Gordon, A. A. Desai, R. A. Knight, R. A. Humerickhouse, J. Qian, G. B. Gordon, and R. Figlin Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6689 - 6695. [Abstract] [Full Text] [PDF]

				R. M. Bukowski, F. F. Kabbinavar, R. A. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, H. A. Drabkin, J. Dutcher, S. Ryba, Q. Xia, et al. Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4536 - 4541. [Abstract] [Full Text] [PDF]

				E. L. Kwak, J. W. Clark, and B. Chabner Targeted Agents: The Rules of Combination Clin. Cancer Res., September 15, 2007; 13(18): 5232 - 5237. [Abstract] [Full Text] [PDF]

				I. Duran, S. J. Hotte, H. Hirte, E. X. Chen, M. MacLean, S. Turner, L. Duan, G. R. Pond, C. Lathia, S. Walsh, et al. Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors Clin. Cancer Res., August 15, 2007; 13(16): 4849 - 4857. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752. [Abstract] [Full Text] [PDF]

				A. Haferkamp and M. Hohenfellner Medical treatment options in patients with metastatic renal cell carcinoma Nephrol. Dial. Transplant., April 1, 2007; 22(4): 996 - 999. [Full Text] [PDF]

				J. Tabernero The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220. [Abstract] [Full Text] [PDF]

				B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				B. I. Rini and W.K. Rathmell Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s. [Abstract] [Full Text] [PDF]

				J. A. Sosman, I. Puzanov, and M. B. Atkins Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer Clin. Cancer Res., January 15, 2007; 13(2): 764s - 769s. [Abstract] [Full Text] [PDF]

				B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A. A. Desai, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma N. Engl. J. Med., January 11, 2007; 356(2): 125 - 134. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				R. J. Motzer and R. M. Bukowski Targeted Therapy for Metastatic Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608. [Abstract] [Full Text] [PDF]

				R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer PNAS, November 14, 2006; 103(46): 17426 - 17431. [Abstract] [Full Text] [PDF]

				L. Martin and R. J. Schilder Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects J Natl Compr Canc Netw, October 1, 2006; 4(9): 955 - 966. [Abstract] [PDF]